Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1917 1
1967 1
1969 1
1970 2
1971 1
1972 3
1978 1
1982 2
1988 2
1990 1
1991 3
1994 1
2000 1
2001 1
2002 1
2005 2
2006 2
2009 3
2011 2
2012 1
2013 1
2015 3
2016 2
2017 3
2018 1
2020 4
2021 2
2022 1
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Takashima T, et al. Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27. Lancet Oncol. 2016. PMID: 26617202 Clinical Trial.
Systematic overview of quality of life studies for breast cancer.
Shimozuma K, Okamoto T, Katsumata N, Koike M, Tanaka K, Osumi S, Saito M, Shikama N, Watanabe T, Mitsumori M, Yamauchi C, Hisashige A; Task Force Of The Japanese Breast Cancer Society For "The Development Of Guidelines For Quality Of Life Assessment Studies Of Breast Cancer Patients". Shimozuma K, et al. Among authors: osumi s. Breast Cancer. 2002;9(3):196-202. doi: 10.1007/BF02967589. Breast Cancer. 2002. PMID: 12185329 Review.
Acquired salinity tolerance in rice: Plant growth dataset.
Sriskantharajah K, Osumi S, Chuamnakthong S, Nampei M, Amas JC, Gregorio GB, Ueda A. Sriskantharajah K, et al. Among authors: osumi s. Data Brief. 2020 Jul 15;31:106023. doi: 10.1016/j.dib.2020.106023. eCollection 2020 Aug. Data Brief. 2020. PMID: 32728604 Free PMC article.
Trimetazidine in blood, bile, organs and urine.
Naito SI, Osumi S, Sekishiro K, Hirose M. Naito SI, et al. Among authors: osumi s. Chem Pharm Bull (Tokyo). 1972 Apr;20(4):682-8. doi: 10.1248/cpb.20.682. Chem Pharm Bull (Tokyo). 1972. PMID: 5045611 No abstract available.
49 results